Welcome to our dedicated page for ENDRA Life Sciences SEC filings (Ticker: NDRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ENDRA Life Sciences Inc. filings document a Nasdaq-listed medical technology issuer focused on thermoacoustic biomarker imaging and the TAEUS® Liver device for liver fat assessment in steatotic liver disease, MASLD and MASH. Periodic and current reports disclose operating results, clinical-program updates, research and development spending, liquidity, risk factors and common-stock registration matters.
The company’s SEC record also covers material-event reports on private placement financing, at-the-market equity offering arrangements, digital asset treasury disclosures involving HYPE token holdings, supplemental digital-asset risk factors, Nasdaq continued-listing compliance, workforce-related exit costs and strategic-review matters. Proxy materials document director elections, equity incentive plan amendments, auditor matters and other stockholder voting items.
ENDRA Life Sciences Inc. (NDRA) released a presentation transcript describing proposed transactions under which ASP Isotopes plans to list its helium business by combining Noble Africa, the holding company for Renergen, with ENDRA via a reverse merger. ASP Isotopes expects to own about 89% of the listed Noble Africa, with roughly 10%–11% free float, subject to potential additional capital raising. Management highlighted Renergen’s Virginia Gas Project in South Africa, noting that the plant began cooling and commissioning in August, has reached operating temperature of 4 Kelvin, and is expected to begin producing commercial product by the end of September, positioning the business as a pure‑play, revenue‑generating helium company. The transcript also includes extensive cautionary language about forward‑looking statements and directs ENDRA stockholders to review a planned Form S‑4 registration statement and proxy statement for full details of the proposed merger and related risks.
ENDRA Life Sciences Inc. (NDRA) is the issuer of record for this submission, which reproduces a Form 8-K for ASP Isotopes Inc. ASP Isotopes reports that it issued a press release on September 8, 2026 announcing its inaugural Capital Markets Day held in London and made an accompanying investor presentation available.
The press release is furnished as Exhibit 99.1, and the presentation is available on ASP Isotopes’ website under Investor Relations. ASP Isotopes states that the information is furnished under Regulation FD, is not deemed “filed” under the Exchange Act or Securities Act, and includes forward-looking statements subject to risks described in its Annual Report on Form 10-K and other SEC reports.
ENDRA Life Sciences Inc. (NDRA) is party to proposed transactions under which ASP Isotopes’ subsidiaries Noble Africa LLC and Renergen Limited would combine Renergen’s South African helium and LNG asset with ENDRA, creating a Nasdaq-listed helium-focused company. Renergen’s Virginia Gas Project has begun Phase 1 production this week and targets free cash flow by year-end, with first product shipments expected in September.
Phase 1 is designed for about 70 MCF/day of helium and 2,500 gigajoules/day of LNG. Using example prices of $600/MCF helium and $13–14/gigajoule LNG, management estimates roughly $27 million in annual revenue and about $11 million in gross profit, with higher helium prices potentially increasing gross profit to $15–20 million. Phase 2 is planned at around 900 MCF/day of liquid helium and 34,000 gigajoules/day of LNG, which at illustrative prices of $600/MCF and $14/gigajoule is described as a $370 million revenue, $300 million gross-profit scale project.
Management states Phase 2 is expected to be built under a turnkey EPC contract over about 44 months, with first production targeted for 2030 and the first full year of production in 2031, and to benefit from about $0.5 billion in debt from the U.S. DFC and about $0.25 billion from Standard Bank. The Virginia Gas Project is characterized as a multigenerational, high-concentration helium resource designated as a strategic asset by both South African and U.S. authorities, positioned to serve tight global helium markets, including semiconductor and space-launch demand. All such figures and timelines are forward-looking estimates subject to the extensive risks described, including project execution, financing availability, commodity price volatility and completion and approval of the proposed merger.
ENDRA Life Sciences Inc. (NDRA) is associated as issuer with a report describing a Reg FD communication by ASP Isotopes Inc. ASP Isotopes announced that Tetra4 Proprietary Limited, a subsidiary of Renergen Limited and developer of the Virginia Gas Project, has entered the commissioning phase of ASP Isotopes’ liquid helium plant. The news is conveyed through a press release furnished as an exhibit and is treated as a non-filed, forward‑looking information disclosure under applicable securities laws.
ENDRA Life Sciences Inc. reported that it released a press release on August 17, 2026 announcing its financial results for the quarter ended June 30, 2026. The press release is provided as Exhibit 99.1 to this Form 8-K and is being furnished rather than filed, which limits its treatment under Section 18 of the Exchange Act. The company’s common stock, par value $0.0001 per share, trades under the symbol NDRA on The Nasdaq Stock Market LLC.
ENDRA Life Sciences Inc. reported second quarter 2026 results and highlighted a pending strategic transaction. On June 25, 2026, ENDRA entered into a definitive merger agreement under which Noble Africa LLC will merge with a wholly owned subsidiary of ENDRA and survive as a wholly owned subsidiary. Upon completion, ENDRA will be renamed Noble Africa Inc., giving investors exposure to Renergen’s Virginia Gas Project in South Africa. In connection with the transaction, Noble Africa agreed to private placements expected to generate approximately $50 million in gross proceeds, with closing anticipated concurrently with the merger in the fourth quarter of 2026, subject to stockholder and regulatory approvals.
ENDRA also completed a $3.8 million private placement on May 28, 2026, with the proceeds classified as restricted cash as of June 30, 2026. As of that date, the company held $1.7 million in cash, $3.8 million in restricted cash, and $1.9 million in its digital asset treasury. Research and development expenses fell 39% and sales and marketing expenses fell 92% versus the second quarter of 2025, while total operating expenses rose to $1.5 million, including higher non-cash stock-based compensation. Other income reached $1.6 million, primarily from realized and unrealized gains on digital assets, leading to net income of $159,944 compared with a net loss of $1.2 million a year earlier.
ENDRA Life Sciences reported total assets of $7.9 million at June 30, 2026, up from $3.9 million at year-end 2025, driven by a $3.8 million May 2026 private placement and gains on its new digital asset treasury strategy. Cash and restricted cash rose to $5.5 million, including $3.8 million held as restricted cash under a side-letter tied to a proposed strategic transaction.
For the quarter, ENDRA recorded net income of $159,944, versus a loss of $1.2 million a year earlier, mainly from $1.29 million of unrealized and $0.41 million of realized gains on HYPE tokens plus staking income. For the first six months, it still posted a net loss of $1.15 million, though improved from a $2.26 million loss in 2025, with operating expenses rising to $3.66 million on higher general and administrative and stock-based compensation.
Management discloses substantial doubt about the company’s ability to continue as a going concern, noting cumulative losses of $111.6 million, limited revenues, and dependence on additional financing. The company also entered into a Merger Agreement involving Noble Africa and Renergen and plans to reclassify its common stock into dual-class shares upon closing. Subsequent to quarter-end, ENDRA regained compliance with Nasdaq’s stockholders’ equity requirement but is subject to a one-year monitoring period.
ASP Isotopes Inc. reports that Tetra4 Proprietary Limited, a subsidiary of Renergen Limited and developer of the Virginia Gas Project in South Africa, has entered into a new contract for the sale of liquified natural gas to be produced at that project. This information is furnished under Regulation FD as of August 6, 2026 and is provided via an attached press release, designated as Exhibit 99.1. The company states that these disclosures are not deemed filed for liability purposes under U.S. securities laws and notes that the press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995.
ASP Isotopes Inc. reported that it will host investor meetings at Citi's 2026 Natural Resources Conference on Thursday, August 13, 2026, in Las Vegas, Nevada. This was communicated through a press release dated August 5, 2026, furnished as Exhibit 99.1 under a Regulation FD disclosure.
The press release is treated as “furnished” rather than “filed” and includes forward-looking statements subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
ASP Isotopes outlines progress across its isotope, helium, nuclear fuels and biotech platforms ahead of announcing second-quarter 2026 results. The company highlights that its PET Labs radiopharmacy business is experiencing strong expansion, with 1H 2026 organic revenue growth above 50%, and indicates PET Labs is forecast to generate approximately $14 million of FY 2026 revenue compared with $6 million in 2025. Management describes an aspirational goal for PET Labs to contribute $50–100 million of EBITDA in 2031.
Renergen’s Virginia Gas Project is expected to begin helium production before September 30, 2026, with annualized helium and LNG revenues projected at about $27 million after completion of Phase 1, and a larger Phase 2 targeting annual revenues exceeding $360 million. ASP Isotopes plans a reverse merger that would list Renergen’s holding vehicle Noble Africa on Nasdaq, with ASP Isotopes owning approximately 89% of the combined company, and continues to pursue a separate listing and potential future equity distribution of Quantum Leap Energy. Additional updates cover Silicon‑28 and Carbon‑14 enrichment progress and the planned Alpa Theranostics nanobody-based oncology pipeline.